The cannabis sector continues to gain significant attention among investors. Even with the recent consolidation seen, earnings reports along with fresh updates are bringing increased optimism to investors of the industry. Following Canada’s switch to recreational legalization several new industry events have occurred, including a few new U.S. states making the move towards legalizing pot.
Gallup, a research-based consulting company, has been conducting surveys on public opinion of marijuana since the 1960s. The company has found that 60% of respondents now want to see cannabis legalized nationally and this is as recent as 2016. In comparison, roughly only 25% approved the idea nationwide back in 1995.
Although some cannabis companies are coming up short in regards to earnings, there are others that are reporting some of their largest earnings seen in recent years. This is consistent with the forecasted market growth that analysts are predicting. Spending on legal cannabis worldwide is expected to reach $57 billion by 2027. The adult-use recreational market is anticipated to cover 67% of the spending, while medical marijuana could take up the remaining 33%.
For investors who are seeking exposure to the cannabis sector, but think that a pure-play company may be too risky for their taste, there are several other interesting investment opportunities for consideration.
Premier Health Group, Inc. (PHGRF) (PHGI) announced that as a part of its expansion plans, it will enter the Cannabis clinic space by a series of acquisitions, partnerships and/or launching a new Canada-based chain in the first half of 2019. The company also previously announced its plans to enter the Pharmacy market via acquisition and/or launching a new Canada based pharmacy in H1-2019. Premier is actively reviewing a pipeline of additional pharmacy partners which include bricks and mortar locations for acquisition and strategic new retail opportunities for pharmacies.
“Cannabis clinics fit in perfectly with our existing Telemedicine services and comprehensive app plans. The patient will not only be able to see their family doctor with our app, but also connect with their Cannabis clinic healthcare worker, the education nurse and eventually even the pharmacy or LP that is providing the prescription. This team based and encompassing approach will provide the best and most convenient care for our patients” said Dr. Essam Hamza, CEO.
Premier Health Group is focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry. The company entered the primary care clinic and health care technology business via the HealthVue transaction and obtained access to a group of four Greater Vancouver-based fully integrated, paperless and electronic-medical-record-based medical clinics with a 10-year history, 22 health care professionals and over 100,000 active patients.
Akers Biosciences, Inc. (AKER) annouced today that it will consider a range of potential strategic alternatives including, but not limited to, cannabis related industries. Members its board have met with several cannabis companies at the recent MJBizCon conference in Las Vegas and Akers has engaged the firm of Feuerstein Kulick LLP as a legal advisor as the board continues its evaluation of opportunities.
“The Board of Directors and management of the Company are considering a number of exciting opportunities for business combinations including within the cannabis industry in which we believe opportunities exist for significant value creation. At the same time, we remain focused on our current business operations and customers and look forward to reporting further developments when appropriate.” Commented Howard R. Yeaton, CEO.
Akers develops, manufactures, and supplies rapid screening and testing products designed to deliver quicker and more cost-effective healthcare information to healthcare providers and consumers. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies, while aligning with major healthcare companies and high-volume medical product distributors to maximize product offerings.
New Age Beverages (NBEV) announced its financial results for Q3, gross revenues totaled $15.3 million versus $16.8 million the year prior, while net revenues less discounts, returns and billbacks reached $13.2 million versus $15 million. According to the company, the working capital shortfall prohibited the company’s ability to meet demand during much of the quarter negatively impacting revenue and gross profits, which reached 16% of net sales versus 33% in the prior year.
New Age is engaged in development and marketing of beverages targeted at health-conscious consumers and the company recently announced a line of CBD-infused drinks. The product line was revealed in October at the North American Convenience Store Show in Las Vegas, and includes CBD-infused relaxation teas, sparkling waters and CBD-infused shots.
Brent Willis, CEO mentioned, “New Age continued to progress its strategy to become the world’s leading healthy beverage company in Q3. We significantly strengthened the Company’s balance sheet and cash position. Now, with the distribution breadth of our core brands and our ability to fulfill demand, the impending launch of our CBD portfolio, and next steps with strategic growth opportunities, we are confident in our ability to continue to drive excellent return for shareowners.”
This Blog is an affiliate of Midam Ventures LLC. Pursuant to an agreement between MIDAM VENTURES, LLC and Premier Health Group Inc. MIDAM was hired for a period from 10/1/2018–4/1/2019 to publicly disseminate information about Premier Health Group Inc. Midam was paid $100,000 (CASH) & “500,000” shares of restricted common shares, they own zero shares that were purchased in the open market. Once the (6) six-month restriction is complete on 4/1/2018, Midam plans to sell the “500,000” shares of Premier Health Group Inc. that they hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. Midam may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Click here for full Midam disclaimer.